20240304-招银国际-中国医药_行业估值吸引_看好创新龙头_5页_1mb

Summary of Chinese Pharmaceutical Industry Analysis

Key Highlights from the Report

• Industry Valuation: The MSCI China Healthcare Index has experienced a 12.2% year-to-date decline, outperforming the MSCI China Index by 27.9% negatively. The dynamic P/E ratio of the index has retreated to 27.2x, below the 12-year historical average. Many leading companies maintain dynamic P/E ratios well below historical levels.
• 2023 Performance and Challenges: In 2023, China's pharmaceutical sector faced significant pressure due to regulatory intensification and the COVID-19 income boom effect. National health insurance revenue fell 12%, while total expenditure decreased 10%. The pharmaceutical manufacturing sector saw revenue decline 37% and profit total drop 151%, indicating alignment with医保支出 trends.
• Outlook for 2024: With industry regulation stabilizing and COVID impacts fading, the sector is expected to return to healthy growth, supported by overseas market expansion and policy improvements for innovation.
• Innovation Focus: GLP-1 Drugs:
  • Zealand Pharma and Bayer HealthCare reported positive phase II data for survodutide, showing high rates of NASH reversal and robust secondary endpoints. BeiGene's Mazdutide had strong results in obesity trials, with a 73.3% liver fat reduction at 24 weeks. The company submitted a NMPA application for weight loss use.
  • Viking Therapeutics' VK2735 demonstrated significant weight loss (13.1% in high-dose group) but faced safety concerns due to 20% patient dropouts.
  • GLP-1 and other long-term assets like ADCs are viewed as promising investment opportunities.

Policy and Market Developments

• Artificial Joint Procurement: A 3-year contract renewal announced on February 23, 2024, is expected to benefit domestic leaders by stabilizing market share and pricing. Further details on bidding rules are anticipated.
• Supporting Factors for Investment:
  • Policy optimism: Improved医保 coverage for innovations, accelerated domestic substitution through medical device procurement, and post-corruption demand recovery in hospitals.
  • Overseas Expansion: Growing potential for drug out-licensing and market entry in innovative pharmaceuticals and medical devices.
  • Valuation Advantages: Most industry leaders have below-average P/E ratios, deviating typically by more than one standard deviation from historical norms.

Investment Recommendations

• Suggest buying companies with strong overseas potential, such as BeiGene and Innovent Biologics, and those with robust growth in Chinese healthcare services, like Solid Trust (2273HK) and others.
• Specific recommendations include: Biotech firms like BeiGene (rating: Buy), Innovent (Buy); medical device companies like Mindray (300760CH); and healthcare services providers like Solid Trust (2273HK).
• Key valuation metrics show potential upside for included companies, with target prices and growth expectations for FY24 providing investment targets.

Disclaimer

• Analysis based on internal research, subject to market risks and uncertainties. Specific terms, analyst declarations, and regulatory disclosures apply, including limitations on distribution.

（Note: This summary adheres toMarkdown format for structured content.）